128456-13-3

Usage

Uses

Used in Pharmaceutical Research and Development:
3-chloro-N-(pyridin-2-yl)propanamide is utilized as a reagent or intermediate in the synthesis of pharmaceutical compounds. Its unique structure, which includes a chlorine atom and a pyridine ring, may contribute to the development of new drugs with specific therapeutic effects.
Used in Chemical Synthesis:
In the chemical industry, 3-chloro-N-(pyridin-2-yl)propanamide may serve as a building block for the creation of more complex molecules with various applications. Its versatility in chemical reactions could be harnessed to produce a range of products, from pharmaceuticals to specialty chemicals.
Used in Drug Discovery:
Due to its potential biological activities, 3-chloro-N-(pyridin-2-yl)propanamide could be explored in drug discovery programs. It may possess properties that make it a candidate for further optimization and development into a drug with therapeutic benefits.
Note: The specific applications and industries for 3-chloro-N-(pyridin-2-yl)propanamide are not explicitly detailed in the provided materials. The uses listed above are inferred based on its description as a chemical compound with potential pharmaceutical applications. Further research and development would be necessary to confirm its practical applications in various industries.

Upstream product

• 504-29-0 2-aminopyridine 
• 625-36-5 2-chloropropionyl chloride 

Relevant academic research and scientific papers

Synthesis and antimalarial activity of N-benzylated (N-arylcarbamoyl)alkylphosphonic acid derivatives

A series of novel and readily accessible N-benzylated (N-arylcarbamoyl)alkylphosphonate esters and related compounds have been prepared as potential antimalarial agents. Bioassays reveal that some of these compounds exhibit promising activity against Plasmodium falciparum, and exhibit no significant growth inhibition of HeLa cells.

Exploring DOXP-reductoisomerase binding limits using phosphonated N-aryl and N-heteroarylcarboxamides as DXR inhibitors

DOXP-reductoisomerase (DXR) is a validated target for the development of antimalarial drugs to address the increase in resistant strains of Plasmodium falciparum. Series of aryl- and heteroarylcarbamoylphosphonic acids, their diethyl esters and disodium salts have been prepared as analogues of the potent DXR inhibitor fosmidomycin. The effects of the carboxamide N-substituents and the length of the methylene linker have been explored using in silico docking studies, saturation transfer difference NMR spectroscopy and enzyme inhibition assays using both EcDXR and PfDXR. These studies indicate an optimal linker length of two methylene units and have confirmed the importance of an additional binding pocket in the PfDXR active site. Insights into the constraints of the PfDXR binding site provide additional scope for the rational design of DXR inhibitors with increased ligand-receptor interactions.